Form 8-K Valeant Pharmaceuticals For: Apr 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- L3Harris CEO steps down amid conduct review, shares drop
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Reddit leads social media platforms in revenue growth per user
Valeant Pharma (VRX) Short Interest Surges 56% - Guggenheim
April 11, 2016 5:42 PM EDTIn analyzing the latest short interest data for the Specialty Pharmaceutical sector, Guggenheim's Louise Chen notes that Valeant Pharma (NYSE: VRX) short interest rose 56.1% - the largest increase in the sector.
Valeant Pharma short interest was at 18,021,306 shares as of 03/31/2016, versus 11,548,303... More
Valeant (VRX) Enters Amended Credit Agreement; Extends Date of 10-K Filing, Waives Cross-Default
April 11, 2016 4:28 PM EDTValeant Pharma (NYSE: VRX) disclosed the following on Monday:
Item 1.01. Entry Into a Material Definitive Agreement.
On April 11, 2016, Valeant Pharmaceuticals International, Inc. (the Company) entered into an amendment and waiver (Amendment No. 12) to its Third Amended and Restated Credit and Guaranty Agreement, dated as of February 13, 2012 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the Credit Agreement).
Amendment No. 12 extends the deadline for filing (i) the Companys Form 10-K for the fiscal year ended December 31, 2015 to May 31, 2016 and (ii) the Companys Form 10-Q for the... More
